UY29058A1 - Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato - Google Patents
Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamatoInfo
- Publication number
- UY29058A1 UY29058A1 UY29058A UY29058A UY29058A1 UY 29058 A1 UY29058 A1 UY 29058A1 UY 29058 A UY29058 A UY 29058A UY 29058 A UY29058 A UY 29058A UY 29058 A1 UY29058 A1 UY 29058A1
- Authority
- UY
- Uruguay
- Prior art keywords
- potenciators
- metabotropic glutamate
- compounds
- isoindolone compounds
- receiver
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Abstract
Compuestos de fórmula I: en donde R1,R2,R3,R4,R5,R6,R7,R8, R9 y n tienen los valores definidos para la fórmula I en la memoria descriptiva. También se describen procesos para la preparación de los compuestos y nuevos intermediarios empleados en la preparación, composiciones farmacéuticas que contienen los compuestos y uso terapéutico de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60112504P | 2004-08-13 | 2004-08-13 | |
US68494505P | 2005-05-27 | 2005-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY29058A1 true UY29058A1 (es) | 2006-02-24 |
Family
ID=35428151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY29058A UY29058A1 (es) | 2004-08-13 | 2005-08-11 | Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato |
Country Status (16)
Country | Link |
---|---|
US (1) | US7968570B2 (es) |
EP (2) | EP1778634A1 (es) |
JP (2) | JP5031565B2 (es) |
KR (3) | KR20140116208A (es) |
CN (2) | CN102134214B (es) |
AR (1) | AR050691A1 (es) |
AU (1) | AU2005272738B2 (es) |
BR (1) | BRPI0514005A (es) |
CA (1) | CA2575853C (es) |
IL (1) | IL181116A0 (es) |
MX (1) | MX2007001282A (es) |
NO (1) | NO20070583L (es) |
RU (1) | RU2420517C2 (es) |
TW (1) | TW200613272A (es) |
UY (1) | UY29058A1 (es) |
WO (1) | WO2006020879A1 (es) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080275062A1 (en) * | 2004-01-30 | 2008-11-06 | David Harold Drewry | Chemical Compounds |
TW200613272A (en) * | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
WO2006125180A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
US7868008B2 (en) * | 2005-08-12 | 2011-01-11 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
WO2007021308A1 (en) * | 2005-08-12 | 2007-02-22 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
TW200804347A (en) | 2006-01-10 | 2008-01-16 | Janssen Pharmaceutica Nv | Urotensin II receptor antagonists |
TW200804281A (en) * | 2006-02-16 | 2008-01-16 | Astrazeneca Ab | New metabotropic glutamate receptor-potentiating isoindolones |
TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途 |
WO2007135529A2 (en) * | 2006-05-23 | 2007-11-29 | Pfizer Products Inc. | Azabenzimidazolyl compounds as mglur2 potentiators |
TW200815349A (en) * | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
US20090291983A1 (en) * | 2006-07-12 | 2009-11-26 | Astrazeneca Ab | 3-Oxoisoindoline-1-Carboxamide Derivatives as Analgesic Agents |
WO2008012623A1 (en) * | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
WO2008012622A2 (en) * | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
AU2007281591A1 (en) | 2006-07-31 | 2008-02-07 | Janssen Pharmaceutica, N.V. | Urotensin II receptor antagonists |
ES2627221T3 (es) | 2006-12-28 | 2017-07-27 | Rigel Pharmaceuticals, Inc. | Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200902499A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
AU2008257559B2 (en) * | 2007-05-25 | 2013-10-10 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (MGLU2 receptor) |
US8853392B2 (en) | 2007-06-03 | 2014-10-07 | Vanderbilt University | Benzamide mGluR5 positive allosteric modulators and methods of making and using same |
TWI417100B (zh) * | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途 |
TW200911255A (en) * | 2007-06-07 | 2009-03-16 | Astrazeneca Ab | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841 |
PA8782701A1 (es) * | 2007-06-07 | 2009-01-23 | Janssen Pharmaceutica Nv | Antagonistas del receptor de urotensina ii |
AU2008297876B2 (en) | 2007-09-14 | 2011-07-07 | Addex Pharma S.A. | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
JP5133416B2 (ja) | 2007-09-14 | 2013-01-30 | オルソー−マクニール−ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 1’,3’−二置換−4−フェニル−3,4,5,6−テトラヒドロ−2h,1’h−[1,4’]ビピリジニル−2’−オン |
US8722894B2 (en) | 2007-09-14 | 2014-05-13 | Janssen Pharmaceuticals, Inc. | 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones |
US8034806B2 (en) | 2007-11-02 | 2011-10-11 | Vanderbilt University | Bicyclic mGluR5 positive allosteric modulators and methods of making and using same |
CN101861316B (zh) | 2007-11-14 | 2013-08-21 | 奥梅-杨森制药有限公司 | 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
TW201000461A (en) * | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
TW201000462A (en) * | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
TW201000447A (en) * | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
TW201000446A (en) * | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
AU2012251943B2 (en) * | 2008-06-06 | 2014-09-25 | Astrazeneca Ab | Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators |
SA109300358B1 (ar) * | 2008-06-06 | 2012-11-03 | استرازينيكا ايه بي | مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون |
GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
TW201006801A (en) | 2008-07-18 | 2010-02-16 | Lilly Co Eli | Imidazole carboxamides |
ES2379762T3 (es) | 2008-08-02 | 2012-05-03 | Janssen Pharmaceutica N.V. | Antagonistas del receptor de la urotensina II |
EP2344470B1 (en) | 2008-09-02 | 2013-11-06 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
WO2010039545A2 (en) * | 2008-09-23 | 2010-04-08 | Georgetown University | 1,2-benzisothiazolinone and isoindolinone derivatives |
US8563580B2 (en) | 2008-09-23 | 2013-10-22 | Georgetown University | Flavivirus inhibitors and methods for their use |
CN102186477B (zh) | 2008-10-16 | 2013-07-17 | 奥梅-杨森制药有限公司 | 作为代谢型谷氨酸受体调节剂的吲哚和苯并吗啉衍生物 |
TW201020244A (en) * | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
CN102232074B (zh) | 2008-11-28 | 2014-12-03 | 奥梅-杨森制药有限公司 | 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物 |
BRPI1007624A2 (pt) | 2009-04-09 | 2016-07-26 | Cognition Therapeutics Inc | composto, método para preparar uma composição, composto ou sal farmaceuticamente aceitável deste e uso de um composto ou um sal farmaceuticamente aceitável deste |
RS53075B (en) | 2009-05-12 | 2014-04-30 | Janssen Pharmaceuticals Inc. | 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
BRPI1010831A2 (pt) | 2009-05-12 | 2016-04-05 | Addex Pharmaceuticals Sa | derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2 |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
ES2547730T3 (es) | 2009-07-31 | 2015-10-08 | Cognition Therapeutics, Inc. | Inhibidores del deterioro cognitivo |
WO2011044479A1 (en) * | 2009-10-09 | 2011-04-14 | Celgene Corporation | Processes for the preparation of 2-(1-phenylethyl) isoindolin-1-one compounds |
MX350761B (es) | 2009-12-22 | 2017-09-18 | Vertex Pharma | Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa. |
DK2521722T3 (en) * | 2010-01-07 | 2015-07-20 | Astrazeneca Ab | PROCEDURE FOR THE PREPARATION OF A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 |
US8664214B2 (en) | 2010-03-30 | 2014-03-04 | AbbVie Deutschland GmbH & Co. KG | Small molecule potentiators of metabotropic glutamate receptors I |
US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
EP2566860B1 (en) | 2010-05-06 | 2014-09-10 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds as gpr119 modulators |
WO2012003147A1 (en) * | 2010-07-01 | 2012-01-05 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
EP2603215A4 (en) | 2010-08-11 | 2015-08-05 | Philadelphia Health & Educatio | NEW DOPAMINERGIC D3 RECEPTOR AGONISTS FOR TREATING DYSKINESIA IN PARKINSON'S DISEASE |
US20130203756A1 (en) * | 2010-10-29 | 2013-08-08 | Jamie L. Bunda | Isoindoline pde10 inhibitors |
AU2011328195B2 (en) | 2010-11-08 | 2015-04-02 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
PT2649069E (pt) | 2010-11-08 | 2015-11-20 | Janssen Pharmaceuticals Inc | Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2 |
CA2815002C (en) | 2010-11-08 | 2019-10-22 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
CA2845551C (en) | 2011-08-16 | 2020-06-09 | Georgetown University | Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives |
WO2013056015A1 (en) | 2011-10-14 | 2013-04-18 | Incyte Corporation | Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors |
ES2604958T3 (es) | 2011-10-28 | 2017-03-10 | Vanderbilt University | Análogos de 2-(4-heterociclilbencil)isoindolin-1-ona sustituidos como moduladores alostéricos positivos del receptor muscarínico de acetilcolina M1 |
WO2013129622A1 (ja) | 2012-03-02 | 2013-09-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
CN102911109B (zh) * | 2012-10-29 | 2014-01-15 | 山西医科大学 | 一种6-氨基-5-氟-1-异吲哚啉酮的制备方法 |
JP6211530B2 (ja) * | 2012-11-19 | 2017-10-11 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
IL279202B2 (en) | 2014-01-21 | 2023-09-01 | Janssen Pharmaceutica Nv | Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use |
KR20220051273A (ko) | 2014-01-21 | 2022-04-26 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
US9796672B2 (en) | 2014-01-31 | 2017-10-24 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
KR102349237B1 (ko) | 2014-04-23 | 2022-01-07 | 다케다 야쿠힌 고교 가부시키가이샤 | 알츠하이머 병의 치료를 위한 콜린작동성 무스카린 m1 수용체 양성 알로스테릭 조절인자 활성을 갖는 이소인돌린-1-온 유도체 |
EP3144308B1 (en) | 2014-05-16 | 2020-06-24 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | MnK抑制劑及其相關方法 |
GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
CA3002558A1 (en) | 2015-10-29 | 2017-05-04 | Effector Therapeutics, Inc. | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2 |
BR112018008714A2 (pt) | 2015-10-29 | 2018-10-30 | Effector Therapeutics Inc | inibidores de isoindolina, azaisoindolina, dihidroindenona e dihidroazaindenona da mnk1 e mnk2 |
US10000487B2 (en) | 2015-11-20 | 2018-06-19 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers |
EP3426652B1 (en) * | 2016-03-10 | 2021-12-01 | Astrazeneca AB | Novel inhibitors of phosphatidylinositol 3-kinase gamma |
KR102539877B1 (ko) | 2016-09-12 | 2023-06-05 | 인테그랄 헬스 인코퍼레이티드 | Gpr120 조정제로서 유용한 이환형 화합물 |
CA3041033A1 (en) | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Monocyclic compounds useful as gpr120 modulators |
CN110719781A (zh) | 2017-02-14 | 2020-01-21 | 效应治疗股份有限公司 | 取代的哌啶MnK抑制剂及其相关方法 |
GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
US11214540B2 (en) | 2017-05-15 | 2022-01-04 | Cognition Therapeutics, Inc. | Compositions for treating neurodegenerative diseases |
JP7135007B2 (ja) * | 2017-07-31 | 2022-09-12 | 武田薬品工業株式会社 | 複素環化合物 |
EP3870178A4 (en) | 2018-10-24 | 2022-08-03 | Effector Therapeutics Inc. | CRYSTALLINE FORMS OF MNK INHIBITORS |
US11078204B2 (en) | 2018-11-13 | 2021-08-03 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
WO2020102216A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Substituted heterocyclic derivatives as pi3k inhibitors |
US11161838B2 (en) | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
KR20220040294A (ko) * | 2020-09-23 | 2022-03-30 | 씨엔지바이오 주식회사 | 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물 |
KR20220040291A (ko) * | 2020-09-23 | 2022-03-30 | 씨엔지바이오 주식회사 | 4-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE620654C (de) * | 1933-04-29 | 1935-10-24 | Smith & Sons Ltd S | Geschwindigkeitsanzeiger |
US3579524A (en) * | 1968-06-05 | 1971-05-18 | Miles Lab | 2-aminoalkyl derivatives of phthalimidines |
US3993617A (en) * | 1975-10-30 | 1976-11-23 | Morton-Norwich Products, Inc. | Antifungal 2-substituted phthalimidines |
WO1992017448A1 (en) | 1991-04-01 | 1992-10-15 | Kyowa Hakko Kogyo Co., Ltd. | 3-methyleneisoindolin-1-one derivative |
TW219935B (es) * | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
JPH06220044A (ja) * | 1991-12-25 | 1994-08-09 | Mitsubishi Kasei Corp | ベンズアミド誘導体 |
EP0602814A1 (en) | 1992-12-18 | 1994-06-22 | Takeda Chemical Industries, Ltd. | Crystal forms of optically active isoindolines and their use |
US5681954A (en) | 1993-05-14 | 1997-10-28 | Daiichi Pharmaceutical Co., Ltd. | Piperazine derivatives |
WO1999026927A2 (en) * | 1997-11-21 | 1999-06-03 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
HUP0302966A2 (hu) | 2000-07-31 | 2003-12-29 | Smithkline Beecham P.L.C. | Karboxamid-vegyületek és alkalmazásuk humán 11CBY receptor antagonistákként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
RU2315746C2 (ru) | 2001-08-09 | 2008-01-27 | Оно Фармасьютикал Ко., Лтд. | Производные карбоновых кислот и фармацевтическое средство, содержащее их в качестве активного ингредиента |
CA2468067A1 (en) * | 2001-11-30 | 2003-06-12 | Merck & Co., Inc. | Metabotropic glutamate receptor-5 modulators |
AU2003226927A1 (en) | 2002-04-09 | 2003-10-27 | 7Tm Pharma A/S | Novel carboxamide compounds for use in mch receptor related disorders |
FR2840302B1 (fr) | 2002-06-03 | 2004-07-16 | Aventis Pharma Sa | Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
DE10238865A1 (de) * | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US20040242572A1 (en) * | 2002-08-24 | 2004-12-02 | Boehringer Ingelheim International Gmbh | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture |
GB0223232D0 (en) * | 2002-10-07 | 2002-11-13 | Pfizer Ltd | Chemical compounds |
WO2004087048A2 (en) | 2003-03-26 | 2004-10-14 | Merck & Co. Inc. | Benzamide modulators of metabotropic glutamate receptors |
GB0308025D0 (en) | 2003-04-07 | 2003-05-14 | Glaxo Group Ltd | Compounds |
US20070135485A1 (en) | 2003-10-22 | 2007-06-14 | Gillig James R | Novel mch receptor antagonists |
US20080275062A1 (en) | 2004-01-30 | 2008-11-06 | David Harold Drewry | Chemical Compounds |
KR101197482B1 (ko) * | 2004-03-05 | 2012-11-09 | 닛산 가가쿠 고교 가부시키 가이샤 | 이속사졸린 치환 벤즈아미드 화합물 및 유해생물 방제제 |
CA2558278A1 (en) * | 2004-03-05 | 2005-09-15 | Banyu Pharmaceutical Co., Ltd. | Diaryl-substituted five-membered heterocycle derivative |
TW200613272A (en) * | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
-
2005
- 2005-08-09 TW TW094126958A patent/TW200613272A/zh unknown
- 2005-08-11 AR ARP050103330A patent/AR050691A1/es active Pending
- 2005-08-11 UY UY29058A patent/UY29058A1/es unknown
- 2005-08-12 KR KR1020147023040A patent/KR20140116208A/ko not_active Application Discontinuation
- 2005-08-12 CA CA2575853A patent/CA2575853C/en not_active Expired - Fee Related
- 2005-08-12 JP JP2007525831A patent/JP5031565B2/ja not_active Expired - Fee Related
- 2005-08-12 BR BRPI0514005-6A patent/BRPI0514005A/pt not_active IP Right Cessation
- 2005-08-12 CN CN201010623175XA patent/CN102134214B/zh not_active Expired - Fee Related
- 2005-08-12 EP EP05785509A patent/EP1778634A1/en not_active Withdrawn
- 2005-08-12 RU RU2007103769/04A patent/RU2420517C2/ru not_active IP Right Cessation
- 2005-08-12 KR KR1020137017097A patent/KR20130082183A/ko not_active Application Discontinuation
- 2005-08-12 EP EP11160550A patent/EP2357169A1/en not_active Withdrawn
- 2005-08-12 US US11/659,149 patent/US7968570B2/en not_active Expired - Fee Related
- 2005-08-12 AU AU2005272738A patent/AU2005272738B2/en not_active Ceased
- 2005-08-12 MX MX2007001282A patent/MX2007001282A/es active IP Right Grant
- 2005-08-12 CN CN2005800347868A patent/CN101039907B/zh not_active Expired - Fee Related
- 2005-08-12 WO PCT/US2005/028760 patent/WO2006020879A1/en active Application Filing
-
2007
- 2007-01-31 NO NO20070583A patent/NO20070583L/no not_active Application Discontinuation
- 2007-02-01 IL IL181116A patent/IL181116A0/en unknown
- 2007-02-01 KR KR1020077002667A patent/KR101477553B1/ko not_active IP Right Cessation
-
2012
- 2012-05-07 JP JP2012105883A patent/JP5658195B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP5658195B2 (ja) | 2015-01-21 |
JP5031565B2 (ja) | 2012-09-19 |
WO2006020879A1 (en) | 2006-02-23 |
CN102134214B (zh) | 2013-05-22 |
JP2012180364A (ja) | 2012-09-20 |
RU2420517C2 (ru) | 2011-06-10 |
KR20140116208A (ko) | 2014-10-01 |
JP2008509926A (ja) | 2008-04-03 |
IL181116A0 (en) | 2007-07-04 |
CN101039907B (zh) | 2011-02-23 |
CA2575853C (en) | 2014-09-23 |
EP2357169A1 (en) | 2011-08-17 |
KR20070097405A (ko) | 2007-10-04 |
US20090275578A1 (en) | 2009-11-05 |
KR20130082183A (ko) | 2013-07-18 |
EP1778634A1 (en) | 2007-05-02 |
MX2007001282A (es) | 2007-04-18 |
KR101477553B1 (ko) | 2014-12-30 |
US7968570B2 (en) | 2011-06-28 |
CN101039907A (zh) | 2007-09-19 |
BRPI0514005A (pt) | 2008-05-27 |
TW200613272A (en) | 2006-05-01 |
AU2005272738B2 (en) | 2012-04-05 |
NO20070583L (no) | 2007-03-08 |
CA2575853A1 (en) | 2006-02-23 |
AR050691A1 (es) | 2006-11-15 |
AU2005272738A1 (en) | 2006-02-23 |
CN102134214A (zh) | 2011-07-27 |
RU2007103769A (ru) | 2008-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY29058A1 (es) | Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato | |
UY30141A1 (es) | Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato | |
UY31127A1 (es) | Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841 | |
UY28764A1 (es) | Compuestos poliheterocíclicos y su uso como antagonistas del receptor de glutamato metabotrópico | |
UY31124A1 (es) | Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842 | |
UY28763A1 (es) | Compuestos de tetrazol y su uso como antagonistas del receptor de glutamato metabotrópico | |
UY31183A1 (es) | Derivados de pirazinona y procesos para su preparación | |
UY28760A1 (es) | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotrópico | |
UY28766A1 (es) | Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico | |
UY29735A1 (es) | Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos | |
UY28765A1 (es) | Compuestos de piperazina acetilínica y su uso como antagonistas del receptor de glutamato metabotrópico | |
ECSP066856A (es) | Compuestos novedosos como moduladores del receptor opioide | |
UY31481A1 (es) | Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones | |
CY1109015T1 (el) | Διφαινυλ ενωσεις χρησιμες ως ανταγωνιστες μουσκαρινικου υποδοχεα | |
UY31870A (es) | Receptor metabotrópico de glutamato potenciadores 286 | |
DOP2007000018A (es) | Moduladores de indol sulfonamida de receptores de progesterona | |
DE602006006712D1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
UY29798A1 (es) | Derivados de carboxamida como antagonistas del receptor muscarínico | |
UY31071A1 (es) | Derivados heterociclicos sustituidos y su uso farmaceutico y composiciones | |
UY29818A1 (es) | Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos | |
CR10497A (es) | Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38 | |
UY29768A1 (es) | Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones | |
BRPI0519709A2 (pt) | derivados de tetralina e indano e usos dos mesmos como antagonistas de 5-ht | |
UY28694A1 (es) | Nuevos compuestos | |
ECSP088603A (es) | Nuevas n-(fluor-pirazinil)-fenilsulfonamidas como moduladores del receptor de quimioquina ccr4 |